GLOBALT Investments LLC GA trimmed its position in shares of Merck & Co., Inc. (NYSE:MRK – Free Report) by 32.8% in the fourth quarter, Holdings Channel.com reports. The firm owned 66,039 shares of the company’s stock after selling 32,306 shares during the period. GLOBALT Investments LLC GA’s holdings in Merck & Co., Inc. were worth $6,570,000 as of its most recent SEC filing.
Several other hedge funds also recently added to or reduced their stakes in the stock. Midwest Capital Advisors LLC acquired a new stake in shares of Merck & Co., Inc. in the 4th quarter valued at about $26,000. Financial Life Planners acquired a new stake in shares of Merck & Co., Inc. in the 4th quarter valued at about $28,000. Noble Wealth Management PBC acquired a new stake in shares of Merck & Co., Inc. in the 4th quarter valued at about $28,000. Halbert Hargrove Global Advisors LLC acquired a new stake in shares of Merck & Co., Inc. in the 4th quarter valued at about $28,000. Finally, Promus Capital LLC acquired a new stake in shares of Merck & Co., Inc. in the 4th quarter valued at about $30,000. 76.07% of the stock is owned by institutional investors and hedge funds.
Merck & Co., Inc. Stock Performance
NYSE:MRK opened at $94.72 on Monday. Merck & Co., Inc. has a twelve month low of $81.04 and a twelve month high of $134.63. The company has a current ratio of 1.36, a quick ratio of 1.15 and a debt-to-equity ratio of 0.79. The company has a 50-day moving average of $93.57 and a 200-day moving average of $101.78. The firm has a market cap of $239.27 billion, a price-to-earnings ratio of 14.07, a price-to-earnings-growth ratio of 0.77 and a beta of 0.35.
Merck & Co., Inc. Dividend Announcement
The firm also recently disclosed a quarterly dividend, which will be paid on Monday, April 7th. Stockholders of record on Monday, March 17th will be given a dividend of $0.81 per share. The ex-dividend date of this dividend is Monday, March 17th. This represents a $3.24 annualized dividend and a dividend yield of 3.42%. Merck & Co., Inc.’s dividend payout ratio (DPR) is 48.14%.
Merck & Co., Inc. announced that its board has initiated a share repurchase program on Tuesday, January 28th that authorizes the company to repurchase $10.00 billion in shares. This repurchase authorization authorizes the company to repurchase up to 4.1% of its shares through open market purchases. Shares repurchase programs are typically a sign that the company’s board of directors believes its shares are undervalued.
Wall Street Analysts Forecast Growth
A number of brokerages have recently issued reports on MRK. Deutsche Bank Aktiengesellschaft lowered shares of Merck & Co., Inc. from a “buy” rating to a “hold” rating and cut their target price for the company from $128.00 to $105.00 in a research note on Tuesday, February 18th. BMO Capital Markets dropped their target price on shares of Merck & Co., Inc. from $105.00 to $96.00 and set a “market perform” rating on the stock in a report on Wednesday, February 5th. HSBC raised shares of Merck & Co., Inc. from a “hold” rating to a “buy” rating and set a $130.00 target price on the stock in a report on Wednesday, December 4th. TD Securities cut shares of Merck & Co., Inc. from a “buy” rating to a “hold” rating and dropped their target price for the stock from $121.00 to $100.00 in a report on Monday, February 10th. Finally, Citigroup dropped their target price on shares of Merck & Co., Inc. from $125.00 to $115.00 and set a “buy” rating on the stock in a report on Wednesday, February 5th. Eleven equities research analysts have rated the stock with a hold rating, nine have assigned a buy rating and three have given a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $117.12.
Check Out Our Latest Analysis on MRK
Insider Buying and Selling at Merck & Co., Inc.
In other Merck & Co., Inc. news, insider Cristal N. Downing sold 2,361 shares of the company’s stock in a transaction dated Thursday, February 6th. The shares were sold at an average price of $88.76, for a total transaction of $209,562.36. Following the completion of the sale, the insider now directly owns 7,085 shares of the company’s stock, valued at approximately $628,864.60. This represents a 24.99 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Inge G. Thulin acquired 2,833 shares of Merck & Co., Inc. stock in a transaction on Thursday, February 6th. The shares were purchased at an average cost of $88.25 per share, with a total value of $250,012.25. Following the completion of the purchase, the director now directly owns 2,933 shares of the company’s stock, valued at approximately $258,837.25. This represents a 2,833.00 % increase in their position. The disclosure for this purchase can be found here. Insiders own 0.09% of the company’s stock.
About Merck & Co., Inc.
Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.
Featured Stories
- Five stocks we like better than Merck & Co., Inc.
- Why Special Dividends Can be a Delightful Surprise for Income Investors
- How to Build the Ultimate Everything ETF Portfolio
- Canadian Penny Stocks: Can They Make You Rich?
- Dutch Bros or Starbucks: Which Coffee Stock Has More Growth?
- Retail Stocks Investing, Explained
- 3 Stocks With High ROE and Market-Beating Growth Potential
Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK – Free Report).
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.